Search Results - "Gansbacher, B."

Second generation of meniscus transplantation: in-vivo study with tissue engineered meniscus replacement by Martinek, V, Ueblacker, P, Bräun, K, Nitschke, S, Mannhardt, R, Specht, K, Gansbacher, B, Imhoff, A B

“…The options available after meniscus loss offer only limited chances for a long-term success. In the following experimental study, we investigated the effect…”
Get full text

Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo by Rognoni, E, Widmaier, M, Haczek, C, Mantwill, K, Holzmüller, R, Gansbacher, B, Kolk, A, Schuster, T, Schmid, R M, Saur, D, Kaszubiak, A, Lage, H, Holm, P S

“…We have earlier described the oncolytic adenovirus vector dl520 that was rendered cancer-specific by deletion of the transactivation domain CR3 of the…”
Get full text

Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo by SCHERER, F, ANTON, M, SCHILLINGER, U, HENKE, J, BERGEMANN, C, KRÜGER, A, GÄNSBACHER, B, PLANK, C

“…Low efficiencies of nonviral gene vectors, the receptor-dependent host tropism of adenoviral or low titers of retroviral vectors limit their utility in gene…”
Get full text

Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer-a phase I clinical trial by Brill, T. H., Kübler, H. R., Randenborgh, H. v., Fend, F., Pohla, H., Breul, J., Hartung, R., Paul, R., Schendel, D. J., Gansbacher, B.

“…Background The purpose of this vaccine study was to determine the safety and feasibility of vaccination with an allogeneic prostate carcinoma cell line, LNCaP,…”
Get full text

Prediction of flap necrosis with laser induced indocyanine green fluorescence in a rat model by Giunta, R.E., Holzbach, T., Taskov, C., Holm, P.S., Brill, T., Busch, R., Gansbacher, B., Biemer, E.

“…Prediction of necrosis has a clinical relevance in all fields of plastic surgery. The new application of indocyanine green (ICG) fluoroscopy in plastic surgery…”
Get full text

Nerve Replacement Strategies for Cavernous Nerves by May, F., Vroemen, M., Matiasek, K., Henke, J., Brill, T., Lehmer, A., Apprich, M., Erhardt, W., Schoeler, S., Paul, R., Blesch, A., Hartung, R., Gansbacher, B., Weidner, N.

“…This article reviews novel restorative therapies for cavernous nerves that may be used to replace resected cavernous nerves at the time of pelvic surgery. A…”
Get full text

Clinical application of immunostimulatory gene transfer by Gansbacher, B

Get more information

Tumor-specific lysis of human renal cell carcinomas by tumor- infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines by Schendel, DJ, Gansbacher, B, Oberneder, R, Kriegmair, M, Hofstetter, A, Riethmuller, G, Segurado, OG

“…Metastatic renal cell carcinoma (RCC), like melanoma, belongs to the small group of human tumors in which partial or complete remission has been observed in…”
Get full text

23.4 The combination of dynamic compression and shear with rvBMP-2 for in-vitro cartilage tissue engineering by Salzmann, G.M, Schmitz, P, Anton, M, Stoddart, M, Grad, S, Milz, S, Tischer, T, Vogt, S, Gansbacher, B, Imhoff, A.B, Alini, M

Get full text

The urokinase plasminogen activator system as a novel target for tumour therapy by Schmitt, M., Wilhelm, O.G., Reuning, U., Krüger, A., Harbeck, N., Lengyel, E., Graeff, H., Gänsbacher, B., Kessler, H., Bürgle, M., Stürzebecher, J., Sperl, S., Magdolen, V.

“…Substantial data have been collected for numerous types of solid cancer, including cancer of the breast, the gastrointestinal and urological tract, the lung,…”
Get full text

IL2 treatment for cancer: from biology to gene therapy by FOA, R, GUARINI, A, GANSBACHER, B

“…In this review we shall discuss the biological rationale and the clinical findings obtained using Interleukin 2 (IL2)-based immunotherapy in the management of…”
Get full text

Retroviral Gene Transfer Induced Constitutive Expression of Interleukin-2 or Interferon-γ in Irradiated Human Melanoma Cells by Gansbacher, B., Zier, K., Cronin, K., Hantzopoulos, P.A., Bouchard, B., Houghton, A., Gilboa, E., Golde, D.

“…Cytokines are important modulators of host antitumor responses. Two of these cytokines, interleukin-2 (IL-2) and interferon γ (IFN-γ), are produced after…”
Get full text

Human gene marker/therapy clinical protocols by Rosenberg, S A, Blaese, R M, Brenner, M K, Deisseroth, A B, Ledley, F D, Lotze, M T, Wilson, J M, Nabel, G J, Cornetta, K, Economou, J S, Freeman, S M, Riddell, S R, Brenner, M, Oldfield, E, Gansbacher, B, Dunbar, C, Walker, R E, Schuening, F G, Roth, J A, Crystal, R G, Welsh, M J, Culver, K, Heslop, H E, Simons, J, Wilmott, R W, Boucher, R C, Siegler, H F, Barranger, J A, Karlsson, S, Kohn, D, Galpin, J E, Raffel, C, Hesdorffer, C, Ilan, J, Cassileth, P, O'Shaughnessy, J, Kun, L E, Das, T K, Wong-Staal, F, Sobol, R E, Haubrich, R, Sznol, M, Rubin, J, Sorcher, E J, Rosenblatt, J, Walker, R, Brigham, K, Vogelzang, N, Hersh, E, Eck, S L

Get more information

Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors by Banke, Ingo J, Arlt, Matthias J E, Pennington, Caroline, Kopitz, Charlotte, Steinmetzer, Torsten, Schweinitz, Andrea, Gansbacher, Bernd, Quigley, James P, Edwards, Dylan R, Stürzebecher, Jörg, Krüger, Achim

“…Although tumors frequently show elevated protease activities, the concept of anti-proteolytic cancer therapy has lost momentum after failure of clinical trials…”
Get more information

Human gene marker/therapy clinical protocols by Rosenberg, S A, Blaese, R M, Brenner, M K, Deisseroth, A B, Ledley, F D, Lotze, M T, Wilson, J M, Nabel, G J, Cornetta, K, Economou, J S, Freeman, S M, Riddell, S R, Oldfield, E, Gansbacher, B, Dunbar, C, Walker, R E, Schuening, F G, Roth, J A, Crystal, R G, Welsh, M J, Culver, K, Heslop, H E, Simons, J, Wilmott, R W, Habib, N A

Get more information

Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity by SCHENDEL, D. J, FALK, C. S, NÖSSNER, E, MAGET, B, KRESSENSTEIN, S, URLINGER, S, TAMPE, R, GANSBACHER, B

“…Even though renal cell carcinomas (RCC) are thought to be immunogenic, many tumors express variations in surface molecules and intracellular proteins that…”
Get full text

Vectors in cancer therapy: how will they deliver? by Blaese, M, Blankenstein, T, Brenner, M, Cohen-Haguenauer, O, Gansbacher, B, Russell, S, Sorrentino, B, Velu, T

Get more information

Cytokine gene therapy by Gansbacher, B

Get more information

Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression by Cignetti, A, Guarini, A, Carbone, A, Forni, M, Cronin, K, Forni, G, Gansbacher, B, Foa, R

“…Previous studies have suggested that some of the limitations associated with the administration of high-dose exogenous interleukin 2 (IL2) may be overcome, at…”
Get more information

High Incidence of Disseminated Intravascular Coagulation During Remission Induction of Adult Patients With Acute Lymphoblastic Leukemia by Sarris, A.H., Kempin, S., Berman, E., Michaeli, J., Little, C., Andreeff, M., Gee, T., Straus, D., Gansbacher, B., Filippa, D., Glaser, B., Clarkson, B.

“…We determined the incidence and complications of disseminated intravascular coagulation (DIC) at presentation and during remission induction of previously…”
Get full text